Alzheimer Europe’s October 2019 newsletter brings you the latest news on developments in the dementia field, across Europe and beyond.
Summaries of a few of our top stories appear below.
Our monthly newsletter has over 8,500 subscribers and we are always happy to receive their comments, or suggested news items to share in future issues.
In Spain, the Government and Autonomous Communities have approved the “Plan Nacional del Alzheimer” (National Alzheimer's Plan) and the general conditions for the acquisition and supply of publicly produced advanced therapy drugs. The Plan was approved during a plenary of the inter-territorial Council of the National Health System (SNS).
Alzheimer Europe is delighted to announce that two Members of the European Parliament have agreed to join the European Alzheimer’s Alliance. The two new members are Manuel Pizarro (S&D, Portugal) and Sergei Stanishev (S&D, Bulgaria).
Biogen has announced plans to seek regulatory approval for Aducanumab, based on a new analysis of a larger dataset from two Phase III trials, which were discontinued in March following a futility analysis of data. Biogen’s new analysis includes data that became available after this.
We are pleased to present the 31st edition of our Dementia in Europe magazine. This edition, published in time for our Annual Conference in The Hague, provides an update on our efforts to make dementia a policy priority in Europe.There is also a supplement on clinical trials.
Neuronet brings together 15 Innovative Medicines Initiative consortium projects working on neurodegenerative disease. The Neuronet programme held four parallel sessions as part of the Alzheimer Europe Conference on 24 and 25 October.
This newsletter received funding under an operating grant from the European Union’s Health Programme (2014-2020).
The content of this newsletter represents the views of the author only and is his/her sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains.